

Pharmacy Benefit Manager Bills - 2019

HB 656 - Establishing a commission to study the impact of financial initiatives for commercially insured members by drug manufacturers on prescription drug prices and health insurance premiums. (Butler)

This bill establishes a commission to study the impact of financial initiatives for commercially insured members by drug manufacturers on prescription drug prices and health insurance premiums.

3/19/19 – Passed the House; division vote 205-131

HB 657 - (New Title) Relative to prescription drugs under the managed care law. (Butler)

This bill clarifies the law regarding prescription drugs under the managed care law.

3/19/19 - Passed the House with Amendment; voice vote

HB 670-FN - Relative to the cost of prescription drugs. (Butler)

This bill requires health insurance carriers to maintain certain information relative to prescription drug costs within their data systems for purposes of the managed care law.

3/19/19 - Passed the House with Amendment; voice vote

HB 703-FN - Relative to providing notice of the introduction of new high-cost prescription drugs. (Butler)

This bill requires prescription drug manufacturers to provide certain notice to the insurance department if they are introducing a new prescription drug to market at a wholesale acquisition cost that exceeds the threshold set for a specialty drug under the Medicare Part D program.

3/19/19 - Passed the House with Amendment; roll call vote 206-141

SB 226-FN - Relative to registration of pharmacy benefit managers, and reestablishing the commission to study greater transparency in pharmaceutical costs and drug rebate programs. (Soucy)

This bill establishes the registration and regulation of pharmacy benefits managers by the insurance commissioner. This bill also reestablishes the commission to study greater transparency in pharmaceutical costs and drug rebate programs.

3/14/19 – Passed the Senate with Amendment; voice vote

3/20/19 - Introduced and referred to House Commerce and Consumer Affairs Committee

Killed or Retained

HB 658-FN - Relative to price increases of drugs under the managed care law. (Butler)

This bill clarifies the content of provider contract standards under the managed care law.

This bill is a result of the commission to study greater transparency in pharmaceutical costs and rebate programs established in 2018, 350.

(The language of this bill is in HB 703).

3/19/19 - Inexpedient to Legislate; voice vote

HB 659 - Relative to reporting of internal pharmaceutical costs. (Butler)

This bill requires the insurance commissioner to request data from health carriers regarding prescription drug benefits which are outsourced to a pharmacy benefit manager or similar entity as part of the preparation for the department's annual hearing requirement.

This bill is a result of the commission to study greater transparency in pharmaceutical costs and rebate programs established in 2018, 350.

3/19/19 - Inexpedient to Legislate; voice vote

HB 671-FN - Relative to pharmacy benefit manager business practices, licensure, and transparency. (Butler)

This bill establishes an RSA chapter governing pharmacy benefit managers.

(Wait for Senate bill to come over).

3/8/2019 - Retained in Committee

SB 222-FN - Relative to licensure of pharmacy benefits managers. (Rosenwald)

This bill establishes the licensure and regulation of pharmacy benefits managers by the insurance commissioner.

(The Senate decided to move forward with SB 226 on the same topic).

3/14/19 – Re-referred to Senate ED&A Committee

3/28/19